WHITE PAPER:
An oxygen-centric, non-stimulant adjunct in peripheral vascular disease: A composite case-study on symptom relief, functional recovery, and microcirculatory perfusion
Authors
Alan P. Xenakis, MD, ScD, MPH, MS
Audra Renee Smith Xenakis, RN, BSN, DNP
1. Why was this case constructed as a composite rather than an individual patient report?
The case was intentionally designed as a composite to preserve patient privacy, avoid anecdotal bias, and emphasize reproducible clinical patterns rather than individual variability. Composite cases allow aggregated observations to be presented in a HIPAA-safe manner while still reflecting real-world clinical trajectories commonly encountered in moderate peripheral vascular disease.
2. What level of disease severity does this case represent?
The case represents moderate peripheral vascular disease without critical limb ischemia, characterized by diminished but palpable pulses, sensory disturbance, and early intermittent claudication, without tissue loss, ulceration, or gangrene.
3. Why is the absence of critical limb ischemia clinically important in this case?
Excluding critical limb ischemia establishes that observed improvements occurred in a population where physiologic recovery is plausible and avoids conflating outcomes with advanced disease requiring urgent revascularization. Importantly, this framing defines the severity scope of the present case and does not preclude benefit in other vascular-compromised contexts, such as diabetic wound healing, where microcirculatory dysfunction rather than acute arterial occlusion is often the dominant limitation.
4. Why was paresthesia selected as a key symptom outcome?
Paresthesia reflects compromised peripheral nerve function, which is highly sensitive to oxygen availability and microvascular diffusion. Improvements in paresthesia can therefore serve as an early indicator of enhanced microcirculatory support before larger functional gains occur.
5. What does the early 20% reduction in paresthesia by week one suggest?
The early reduction suggests that sensory nerve function may respond quickly to improved tissue oxygen availability, preceding more gradual improvements in muscle metabolism and walking tolerance.
6. Why was claudication resolution assessed over six weeks rather than earlier?
Claudication reflects exertional muscle ischemia and typically improves more slowly than sensory symptoms. A six-week timeframe aligns with expected physiologic adaptation rather than acute symptom masking.
7. Why was the six-minute walk test used to assess functional change?
The six-minute walk test is a standardized, low-burden functional assessment that reflects real-world walking capacity and endurance without requiring specialized equipment or invasive testing.
8. How should the 45% improvement in TcPO₂ be interpreted clinically?
The TcPO₂ improvement indicates enhanced transcutaneous oxygen availability and is consistent with improved microcirculatory perfusion. It supports—but does not independently prove—a physiologic mechanism underlying symptom and functional improvement.
9. Why is TcPO₂ particularly relevant in peripheral vascular disease?
TcPO₂ provides a non-invasive surrogate measure of tissue oxygenation, which is directly relevant to both nerve function and muscle metabolism in vascular-compromised extremities.
10. What is the significance of improved capillary refill and warmer extremities?
These bedside findings provide clinical corroboration of improved distal perfusion, reinforcing that TcPO₂ changes were reflected in observable physical examination findings.
11. Why was XenaGen™ positioned as an adjunct rather than a replacement therapy?
The case intentionally frames XenaGen™ as an adjunct to standard-of-care management, not a substitute for established therapies such as risk-factor control, exercise, or revascularization when indicated.
12. Why is the non-stimulant characterization emphasized throughout the case?
Many agents that improve perceived energy rely on sympathetic stimulation, which may increase cardiovascular risk in PVD populations. Emphasizing non-stimulant effects distinguishes physiologic support from arousal-based symptom masking.
13. What is the clinical importance of the absence of tachycardia or blood pressure instability?
The absence of cardiovascular side effects supports the safety profile of an oxygen-centric approach and differentiates it from stimulant-based interventions that may exacerbate vascular risk.
14. Why were sleep quality and nocturnal symptoms included as outcomes?
Nocturnal paresthesia is a common but often under-recognized contributor to fatigue and reduced daytime function. Improvement in sleep continuity suggests broader functional benefit beyond walking capacity alone.
15. What does the temporal sequence of improvement indicate mechanistically?
The sequence—sensory improvement first, followed by functional gains and claudication resolution—aligns with a model of improved tissue oxygen availability rather than acute neuromodulation or stimulant effects.
16. Can these findings be interpreted as causal evidence?
No. This science based quality improvement case represents descriptive and educational observations. However, the findings are internally favorably coherent, directional, and physiologically robust and suggest further clinical discussion.
17. Why were no advanced imaging or angiographic endpoints included?
The case intentionally focuses on clinically meaningful, bedside-relevant findings and functional outcomes rather than advanced imaging or angiographic endpoints to maintain educational clarity and avoid over-interpretation beyond the scope of aggregated observations. Extensive advanced imaging and procedural endpoints are often used in research and interventional studies, but they also contribute to substantial healthcare costs in peripheral vascular disease, which already represents a high expenditure burden in health systems. National analyses show that PAD is associated with large healthcare resource utilization, including procedural and inpatient costs, and that reductions in low-value procedural use require multi-pronged strategies beyond imaging alone. By emphasizing functional and physiologic outcomes aligned with patient experiences and real-world practice, the case aligns clinical signals with economic relevance and avoids promoting high-cost, low-value diagnostics in a context where conservative management and observational outcomes are the focus.
18. What patient population might most plausibly benefit from this approach?
Individuals with moderate peripheral vascular disease who experience persistent paresthesia, reduced walking tolerance, and early intermittent claudication despite stable standard-of-care management may represent a population of interest for further study. This includes patients with functional limitation and sensory symptoms in whom improvements in tissue oxygen availability could plausibly translate into meaningful clinical benefit.
19. What are the primary limitations of this case study?
Key limitations include its composite design, small aggregated sample size, lack of randomization, and reliance on descriptive rather than inferential statistics.
20. What is the primary educational takeaway for clinicians?
The case illustrates that supporting tissue oxygen delivery and microvascular diffusion—without relying on stimulation—may be associated with meaningful improvements in sensory symptoms, functional capacity, and perfusion markers in moderate PVD, warranting oxygen centric adjunct consideration in patient care.
Source: Xenakis, A. R-S. X., & Xenakis, A. X. (2025). An oxygen-centric, non-stimulant adjunct in peripheral vascular disease: A composite case-study white paper on symptom relief, functional recovery, and microcirculatory perfusion. XenaDigm. https://xenadigm.com/qi-white-papers-for-xenagen/